Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 261,738
  • Shares Outstanding, K 42,421
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,000 K
  • 60-Month Beta 1.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.10
Trade CRVS with:

Options Overview

Details
  • Implied Volatility 189.32%
  • Historical Volatility 309.88%
  • IV Percentile 95%
  • IV Rank 72.14%
  • IV High 232.10% on 06/28/21
  • IV Low 78.53% on 09/13/21
  • Put/Call Vol Ratio 0.51
  • Today's Volume 30,438
  • Volume Avg (30-Day) 6,440
  • Put/Call OI Ratio 1.22
  • Today's Open Interest 22,420
  • Open Int (30-Day) 5,361

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.29
  • Number of Estimates 2
  • High Estimate -0.24
  • Low Estimate -0.35
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +12.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.91 +303.45%
on 08/23/21
8.33 -7.44%
on 09/21/21
+5.80 (+303.66%)
since 08/20/21
3-Month
1.86 +314.52%
on 08/20/21
8.33 -7.44%
on 09/21/21
+5.12 (+197.68%)
since 06/21/21
52-Week
1.86 +314.52%
on 08/20/21
8.33 -7.44%
on 09/21/21
+3.41 (+79.30%)
since 09/21/20

Most Recent Stories

More News
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026 - Financial News Media

Palm Beach, FL - September 20, 2021 – FinancialNewsMedia.com News Commentary – Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements...

ONCY : 2.10 (+2.94%)
ONC.TO : 2.68 (+2.29%)
CRVS : 7.81 (+26.58%)
IPHA : 7.41 (-7.95%)
SURF : 7.40 (+0.95%)
CLVS : 4.43 (-3.06%)
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026

PALM BEACH,  Fla., /PRNewswire/ -- Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more effective,...

ONCY : 2.10 (+2.94%)
ONC.TO : 2.68 (+2.29%)
CRVS : 7.81 (+26.58%)
IPHA : 7.41 (-7.95%)
SURF : 7.40 (+0.95%)
CLVS : 4.43 (-3.06%)
Implied Volatility Surging for Corvus Pharmaceuticals (CRVS) Stock Options

Investors need to pay close attention to Corvus Pharmaceuticals (CRVS) stock based on the movements in the options market lately.

CRVS : 7.81 (+26.58%)
BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma

The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.

NVS : 83.05 (+0.30%)
BGNE : 390.57 (-1.99%)
CRVS : 7.81 (+26.58%)
SPRO : 18.99 (-0.05%)
RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study

RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal....

RDHL : 4.80 (+5.49%)
VTVT : 1.7100 (unch)
CRVS : 7.81 (+26.58%)
SPRO : 18.99 (-0.05%)
Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran

Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

ALNY : 184.94 (+0.81%)
VRTX : 185.49 (-0.10%)
CRVS : 7.81 (+26.58%)
SPRO : 18.99 (-0.05%)
BeiGene's (BGNE) BLA for Tislelizumab in ESCC Accepted by FDA

The FDA accepts for review BeiGene's (BGNE) BLA for tislelizumab to treat patients with locally advanced/metastatic esophageal squamous cell carcinoma after prior systemic therapy.

NVS : 83.05 (+0.30%)
BGNE : 390.57 (-1.99%)
CRVS : 7.81 (+26.58%)
SPRO : 18.99 (-0.05%)
Apellis (APLS) Down on Mixed Data From Studies on GA Candidate

Apellis (APLS) posts mixed top-line data from the phase III DERBY and OAKS studies testing pegcetacoplan in adults with geographic atrophy secondary to age-related macular degeneration. Stock falls.

AZN : 58.87 (+0.63%)
CRVS : 7.81 (+26.58%)
SPRO : 18.99 (-0.05%)
APLS : 32.95 (-0.33%)
Global Blood's (GBT) NDA & sNDA for Oxbryta Get Priority Review

The FDA grants priority review to Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to 11 years, as well as to its NDA for a pediatric weight-based formulation of the drug.

VRTX : 185.49 (-0.10%)
GBT : 27.27 (+0.63%)
CRVS : 7.81 (+26.58%)
SPRO : 18.99 (-0.05%)
Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company's management will participate in two upcoming investor conferences in September:...

CRVS : 7.81 (+26.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible...

See More

Key Turning Points

3rd Resistance Point 9.24
2nd Resistance Point 8.07
1st Resistance Point 7.12
Last Price 7.81
1st Support Level 5.00
2nd Support Level 3.83
3rd Support Level 2.88

See More

52-Week High 8.33
Last Price 7.81
Fibonacci 61.8% 5.86
Fibonacci 50% 5.09
Fibonacci 38.2% 4.33
52-Week Low 1.86

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar